Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis
Open Access
- 1 December 2004
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 63 (12) , 1611-1617
- https://doi.org/10.1136/ard.2003.019703
Abstract
Objective: To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic knee osteoarthritis (OA). Patients and methods: A 1 year prospective, multicentre, randomised, double blind, placebo controlled study of 301 patients aged >50 years with painful and radiological medial knee OA. Patients were randomly assigned into three groups receiving: (1) three courses of three IA injections of hyaluronic acid (HA) + oral placebo; (2) IA injections of saline solution + diacerein 100 mg/day; (3) IA injections of saline solution + oral placebo. Demographic data and symptomatic criteria—pain, Lequesne’s index, patient’s global assessment of disease activity, percentage of painful days—were obtained during the study; primary structural criterion was JSW. Efficacy criteria were changes in pain VAS, joint space narrowing (JSN), and percentage of progressors (JSN >0.5 mm). An intention to treat analysis was used for symptomatic variables, and completer analysis for structural variables. Results: Baseline characteristics were similar between the three groups. Mean (SD) improvement in pain VAS was clinically relevant (−33.9 (27.3), n = 301), but with no difference between the groups (p = 0.96). JSW deteriorated (−0.09 (0.55) mm, n = 277, p = 0.01), but with no difference between the groups (p = 0.82). Percentages of progressors were 17.7, 18.9, and 20.3% (p = 0.90), in groups 1, 2, and 3, respectively. Conclusion: A weak but statistically significant structural deterioration occurred over 1 year, together with clinically relevant symptomatic improvement in patients receiving oral drug and iterative IA injections. Symptomatic and/or structural effects for both this new HA compound and diacerein were not demonstrated.Keywords
This publication has 46 references indexed in Scilit:
- 8 Intra-articular therapy in osteoarthritisBailliere's Clinical Rheumatology, 1997
- OsteoarthritisThe Lancet, 1997
- Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan®) in osteoarthritis of the kneeOsteoarthritis and Cartilage, 1997
- A systematic review of randomized controlled trialsof pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodologySeminars in Arthritis and Rheumatism, 1997
- KNEE JOINT SPACE WIDTH MEASUREMENT: AN EXPERIMENTAL STUDY OF THE INFLUENCE OF RADIOGRAPHIC PROCEDURE AND JOINT POSITIONINGRheumatology, 1996
- Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group.Annals of the Rheumatic Diseases, 1996
- Atlas of individual radiographic features in osteoarthritis.1995
- Functions of hyaluronan.Annals of the Rheumatic Diseases, 1995
- A new approach to the treatment of osteoarthritis: viscosupplementationOsteoarthritis and Cartilage, 1993
- High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trialOsteoarthritis and Cartilage, 1993